In this study, we verified the high expression of TNFRSF12A in STAD by bioinformatics as well as in vitro experiments and found that it may affect STAD immunotherapy by influencing immune infiltration, a finding that provides a new therapeutic target for personalized treatment of STAD. This evidence concerns the gene TNFRSF12A and gastric adenocarcinoma.